Hyunji Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hyunji Lee has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Jongsun Park
Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
15 shared publications - Jisoo Park
Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon, South Korea
13 shared publications Quangdon Tran
Department of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, 35015, South Korea; Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, 35015, South Korea
11 shared publicationsYoungeun Hong
Department of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, 35015, South Korea; Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, 35015, South Korea
11 shared publicationsMinhee Kim
Department of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, 35015, South Korea; Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, 35015, South Korea
8 shared publicationsHyeonjeong Cho
Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon, 35015, South Korea
7 shared publications
Latest Publications
- 1 July 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 528 (3) , 478-484
FCHO1560−571 peptide, a PKB kinase motif, inhibits tumor progression
- 1 July 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 528 (3) , 478-484
FCHO1560−571 peptide, a PKB kinase motif, inhibits tumor progression
- Open Access
- 18 June 2020
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 27 (12) , 3321-3336
Yin Yang 1 is required for PHD finger protein 20-mediated myogenic differentiation in vitro and in vivo
The development of skeletal muscle requires progression of a highly ordered cascade of events comprising myogenic lineage commitment, myoblast proliferation, and terminal differentiation. The process of myogenesis is controlled by several myogenic transcription factors that act as terminal effectors of signaling cascades and produce appropriate developmental stage-specific transcripts. PHD finger protein 20 (PHF20) is a multidomain protein and subunit of a lysine acetyltransferase complex that acetylates histone H4 and p53, but its function is unclear. Notably, it has been reported that PHF20 knockout mice die shortly after birth and display a wide variety of phenotypes within the skeletal and hematopoietic systems. Therefore, the putative role of PHF20 in myogenic differentiation was further investigated. In the present study, we found that protein and mRNA expression levels of PHF20 were decreased during myogenic differentiation in C2C12 cells. At the same time, Yin Yang 1 (YY1) was also decreased during myogenic differentiation. PHF20 overexpression increased YY1 expression during myogenic differentiation, together with a delay in MyoD expression. PHF20 expression enhanced the transcriptional activity of YY1 while shRNA-mediated depletion of PHF20 resulted in the reduction of YY1 promoter activity in C2C12 cells. In addition, PHF20 directly bounds to the YY1 promoter in C2C12 cells. In a similar manner, YY1 expression was elevated while myosin heavy chain expression was decreased in PHF20 transgenic (TG) mice. Histological analysis revealed abnormalities in the shape and length of muscles in PHF20-TG mice. Furthermore, PHF20-TG muscles slowly regenerated after cardiotoxin injection, indicating that PHF20 affected muscle differentiation and regeneration after injury in vivo. Taken together, these results suggested that PHF20 plays an important role in myogenic differentiation by regulating YY1.
- 18 June 2020
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 27 (12) , 3321-3336
Open AccessYin Yang 1 is required for PHD finger protein 20-mediated myogenic differentiation in vitro and in vivo
The development of skeletal muscle requires progression of a highly ordered cascade of events comprising myogenic lineage commitment, myoblast proliferation, and terminal differentiation. The process of myogenesis is controlled by several myogenic transcription factors that act as terminal effectors of signaling cascades and produce appropriate developmental stage-specific transcripts. PHD finger protein 20 (PHF20) is a multidomain protein and subunit of a lysine acetyltransferase complex that acetylates histone H4 and p53, but its function is unclear. Notably, it has been reported that PHF20 knockout mice die shortly after birth and display a wide variety of phenotypes within the skeletal and hematopoietic systems. Therefore, the putative role of PHF20 in myogenic differentiation was further investigated. In the present study, we found that protein and mRNA expression levels of PHF20 were decreased during myogenic differentiation in C2C12 cells. At the same time, Yin Yang 1 (YY1) was also decreased during myogenic differentiation. PHF20 overexpression increased YY1 expression during myogenic differentiation, together with a delay in MyoD expression. PHF20 expression enhanced the transcriptional activity of YY1 while shRNA-mediated depletion of PHF20 resulted in the reduction of YY1 promoter activity in C2C12 cells. In addition, PHF20 directly bounds to the YY1 promoter in C2C12 cells. In a similar manner, YY1 expression was elevated while myosin heavy chain expression was decreased in PHF20 transgenic (TG) mice. Histological analysis revealed abnormalities in the shape and length of muscles in PHF20-TG mice. Furthermore, PHF20-TG muscles slowly regenerated after cardiotoxin injection, indicating that PHF20 affected muscle differentiation and regeneration after injury in vivo. Taken together, these results suggested that PHF20 plays an important role in myogenic differentiation by regulating YY1.
- Open Access
- 25 February 2020
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11, 130
Relationship Between Ginsenoside Rg3 and Metabolic Syndrome
Metabolic syndrome is an important public health issue and is associated with a more affluent lifestyle. Many studies of metabolic syndrome have been reported, but its pathogenesis remains unclear and there is no effective treatment. The ability of natural compounds to ameliorate metabolic syndrome is currently under investigation. Unlike synthetic chemicals, such natural products have proven utility in various fields. Recently, ginsenoside extracted from ginseng and ginseng root are representative examples. For example, ginseng is used in dietary supplements and cosmetics. In addition, various studies have reported the effects of ginsenoside on metabolic syndromes such as obesity, diabetes, and hypertension. In this review, we describe the potential of ginsenoside Rg3, a component of ginseng, in the treatment of metabolic syndrome.
- 25 February 2020
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11, 130
Open AccessRelationship Between Ginsenoside Rg3 and Metabolic Syndrome
Metabolic syndrome is an important public health issue and is associated with a more affluent lifestyle. Many studies of metabolic syndrome have been reported, but its pathogenesis remains unclear and there is no effective treatment. The ability of natural compounds to ameliorate metabolic syndrome is currently under investigation. Unlike synthetic chemicals, such natural products have proven utility in various fields. Recently, ginsenoside extracted from ginseng and ginseng root are representative examples. For example, ginseng is used in dietary supplements and cosmetics. In addition, various studies have reported the effects of ginsenoside on metabolic syndromes such as obesity, diabetes, and hypertension. In this review, we describe the potential of ginsenoside Rg3, a component of ginseng, in the treatment of metabolic syndrome.
- 7 February 2020
- Published by Springer Nature in Toxicological Research
- Vol. 36 (2) , 123-130
Myristoylated TMEM39AS41, a cell-permeable peptide, causes lung cancer cell death
Lung cancer is the most common cause of cancer-associated death worldwide. Most patients with non-small cell lung cancer die within several years of the initial diagnosis, and new therapies are desperately needed. Transmembrane protein (TMEM) 39AS41, a synthetic peptide, was generated from the protein kinase B substrate motif 34GLRNRNGSAIGLPVP48 found in the human TMEM39A protein. Myristic acid was conjugated to the N-terminus of the peptide to confer cell permeability. In this study, we found that in vitro TMEM39AS41 peptide led to cell death via inhibition of inflammation/autophagy pathways in KRAS-mutated cell and tissues. In addition, TMEM39A, at a dose of 30 mg/kg, significantly suppressed tumor growth in KRASLA1 non-small cell lung cancer mice. These results suggest that the TMEM39AS41 peptide could have therapeutic potential for lung cancer.
- 7 February 2020
- Published by Springer Nature in Toxicological Research
- Vol. 36 (2) , 123-130
Myristoylated TMEM39AS41, a cell-permeable peptide, causes lung cancer cell death
Lung cancer is the most common cause of cancer-associated death worldwide. Most patients with non-small cell lung cancer die within several years of the initial diagnosis, and new therapies are desperately needed. Transmembrane protein (TMEM) 39AS41, a synthetic peptide, was generated from the protein kinase B substrate motif 34GLRNRNGSAIGLPVP48 found in the human TMEM39A protein. Myristic acid was conjugated to the N-terminus of the peptide to confer cell permeability. In this study, we found that in vitro TMEM39AS41 peptide led to cell death via inhibition of inflammation/autophagy pathways in KRAS-mutated cell and tissues. In addition, TMEM39A, at a dose of 30 mg/kg, significantly suppressed tumor growth in KRASLA1 non-small cell lung cancer mice. These results suggest that the TMEM39AS41 peptide could have therapeutic potential for lung cancer.
- Open Access
- 15 October 2019
- Published by Springer Nature in Toxicological Research
- Vol. 35 (4) , 361-369
1,2-Dichloropropane (1,2-DCP)-Induced Angiogenesis in Dermatitis
Meiying Jin, Youngeun Hong, Hyunji Lee, Quangdon Tran, Hyeonjeong Cho, Minhee Kim, So Hee Kwon, Nak Heon Kang, Jisoo Park and Jongsun Park. ToxicolRes 2019;35:361-9. https://doi.org/10.5487/TR.2019.35.4.361
- 15 October 2019
- Published by Springer Nature in Toxicological Research
- Vol. 35 (4) , 361-369
Open Access1,2-Dichloropropane (1,2-DCP)-Induced Angiogenesis in Dermatitis
Meiying Jin, Youngeun Hong, Hyunji Lee, Quangdon Tran, Hyeonjeong Cho, Minhee Kim, So Hee Kwon, Nak Heon Kang, Jisoo Park and Jongsun Park. ToxicolRes 2019;35:361-9. https://doi.org/10.5487/TR.2019.35.4.361
- 1 October 2019
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 242, 112054
Ginsenoside Rg3 upregulates myotube formation and mitochondrial function, thereby protecting myotube atrophy induced by tumor necrosis factor-alpha
- 1 October 2019
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 242, 112054
Ginsenoside Rg3 upregulates myotube formation and mitochondrial function, thereby protecting myotube atrophy induced by tumor necrosis factor-alpha
- 1 August 2019
- Published by Elsevier in Laboratory Investigation
- Vol. 99 (8) , 1157-1172
Anti-cancer effect of doxorubicin is mediated by downregulation of HMG-Co A reductase via inhibition of EGFR/Src pathway
- 1 August 2019
- Published by Elsevier in Laboratory Investigation
- Vol. 99 (8) , 1157-1172
Anti-cancer effect of doxorubicin is mediated by downregulation of HMG-Co A reductase via inhibition of EGFR/Src pathway
- Open Access
- 1 July 2019
- Published by Elsevier in Journal of Ginseng Research
- Vol. 43 (3) , 431-441
A new role for the ginsenoside RG3 in antiaging via mitochondria function in ultraviolet-irradiated human dermal fibroblasts
- 1 July 2019
- Published by Elsevier in Journal of Ginseng Research
- Vol. 43 (3) , 431-441
Open AccessA new role for the ginsenoside RG3 in antiaging via mitochondria function in ultraviolet-irradiated human dermal fibroblasts
- 1 August 2018
- Published by Elsevier in Cellular Signalling
- Vol. 48, 13-24
S6 kinase 1 plays a key role in mitochondrial morphology and cellular energy flow
- 1 August 2018
- Published by Elsevier in Cellular Signalling
- Vol. 48, 13-24
S6 kinase 1 plays a key role in mitochondrial morphology and cellular energy flow
- Open Access
- 11 June 2018
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 16 (1) , 29
Emerging roles of TRIO and F-actin-binding protein in human diseases
TRIO and F-actin-binding protein (TRIOBP) also referred to as Tara, was originally isolated as a cytoskeleton remodeling protein. TRIOBP-1 is important for regulating F-actin filament reorganization. TRIOBP variants are broadly classified as variant-1 or − 4 and do not share exons. TRIOBP variant-5 contains all exons. Earlier studies indicated that TRIOBP-4/5 mutation is a pivotal element of autosomal recessive nonsyndromic hearing loss. However, recent studies provide clues that TRIOBP variants are associated with other human diseases including cancer and brain diseases. In this review, recent functional studies focusing on TRIOBP variants and its possible disease models are described.
- 11 June 2018
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 16 (1) , 29
Open AccessEmerging roles of TRIO and F-actin-binding protein in human diseases
TRIO and F-actin-binding protein (TRIOBP) also referred to as Tara, was originally isolated as a cytoskeleton remodeling protein. TRIOBP-1 is important for regulating F-actin filament reorganization. TRIOBP variants are broadly classified as variant-1 or − 4 and do not share exons. TRIOBP variant-5 contains all exons. Earlier studies indicated that TRIOBP-4/5 mutation is a pivotal element of autosomal recessive nonsyndromic hearing loss. However, recent studies provide clues that TRIOBP variants are associated with other human diseases including cancer and brain diseases. In this review, recent functional studies focusing on TRIOBP variants and its possible disease models are described.